You need JavaScript to view this

The Treatment of Cancer by a Radioactive Drug: Tritium-Labelled Tetra-Sodium 2-Methyl-1:4-Naphthaquinol Diphosphate; Traitement du Cancer par un Remede Radioactif: Le Diphosphate Tetrasodique de Methyl-2 Naphtoquinone-1,4 Tritie; 041b 0435 0447 0435 043d 0414 ; Tratamiento del Cancer con la Sal Tetrasodica del Acido 2-Metil-1,4-Naftoquinon Difosforico Marcada con Tritio

Abstract

The action of tetra-sodium 2-methyl-1: 4-naphthaquinoI diphosphate (''Synkavit''-Roche Products) as a radiosensitizer will be reviewed together with earlier methods of labelling this and similar molecules. The synthesis of this compound labelled with tritium has been accomplished so as to yield a radiochemically pure drug of specific activity 28 c/mmole (1 atom of tritium/molecule). It will be shown that this compound enters the living cell very rapidly both in-vivo and in-vitro and that cultures of malignant cells incorporate the label to a much greater extent than cultures of normal cells under identical conditions. Preliminary investigations on the use of this drug on patients with advanced, and often otherwise, refractory, malignant conditions will be described; uptake by the bone marrow is less than by the tumour, sometimes by a factor of 5. (author) [French] Les auteurs examinent l'action du diphosphate tetrasodique de methyl-2- naphtoquinone-1,4 ('Synkavit'-Produits Roche) comme radiosensibilisateur, ainsi que les methodes plus anciennes de marquage de ces molecules et de molecules analogues. On a fait la synthese de ce compose marque au tritium, de facon a obtenir un produit pharmaceutique radiochimiquement pur, dont l'activite specifique est de 28 curies par millimole (1 atome de tritium par molecule). Les auteurs demontrent que  More>>
Authors:
Marrian, D. H.; Marshall, Barbara; Mitchell, J. S.; Simon-Reuss, I. [1] 
  1. Department of Radiotherapeutics, University of Cambridge, Cambridge (United Kingdom)
Publication Date:
Feb 15, 1962
Product Type:
Conference
Resource Relation:
Conference: Symposium on the Detection and Use of Tritium in the Physical and Biological Sciences, Vienna (Austria), 3-10 May 1961; Other Information: 10 refs., 3 figs.; Related Information: In: Tritium in the Physical and Biological Sciences. Vol. II. Proceedings of the Symposium on the Detection and Use of Tritium in the Physical and Biological Sciences| 456 p.
Subject:
38 RADIATION CHEMISTRY, RADIOCHEMISTRY AND NUCLEAR CHEMISTRY; 62 RADIOLOGY AND NUCLEAR MEDICINE; BONE MARROW; IN VITRO; IN VIVO; LABELLING; NEOPLASMS; PATIENTS; PHOSPHATES; RADIOSENSITIVITY; RADIOSENSITIZERS; RADIOTHERAPY; REFRACTORIES; REVIEWS; SODIUM; SYNTHESIS; TRITIUM; UPTAKE
OSTI ID:
22188135
Research Organizations:
International Atomic Energy Agency, Vienna (Austria); Joint Commission on Applied Radioactivity of the International Council of Scientific Unions, Paris (France)
Country of Origin:
IAEA
Language:
English
Other Identifying Numbers:
Other: ISSN 0074-1884; TRN: XA13M3702012636
Submitting Site:
INIS
Size:
page(s) 211-216
Announcement Date:
Feb 06, 2014

Citation Formats

Marrian, D. H., Marshall, Barbara, Mitchell, J. S., and Simon-Reuss, I. The Treatment of Cancer by a Radioactive Drug: Tritium-Labelled Tetra-Sodium 2-Methyl-1:4-Naphthaquinol Diphosphate; Traitement du Cancer par un Remede Radioactif: Le Diphosphate Tetrasodique de Methyl-2 Naphtoquinone-1,4 Tritie; 041b 0435 0447 0435 043d 0414 ; Tratamiento del Cancer con la Sal Tetrasodica del Acido 2-Metil-1,4-Naftoquinon Difosforico Marcada con Tritio. IAEA: N. p., 1962. Web.
Marrian, D. H., Marshall, Barbara, Mitchell, J. S., & Simon-Reuss, I. The Treatment of Cancer by a Radioactive Drug: Tritium-Labelled Tetra-Sodium 2-Methyl-1:4-Naphthaquinol Diphosphate; Traitement du Cancer par un Remede Radioactif: Le Diphosphate Tetrasodique de Methyl-2 Naphtoquinone-1,4 Tritie; 041b 0435 0447 0435 043d 0414 ; Tratamiento del Cancer con la Sal Tetrasodica del Acido 2-Metil-1,4-Naftoquinon Difosforico Marcada con Tritio. IAEA.
Marrian, D. H., Marshall, Barbara, Mitchell, J. S., and Simon-Reuss, I. 1962. "The Treatment of Cancer by a Radioactive Drug: Tritium-Labelled Tetra-Sodium 2-Methyl-1:4-Naphthaquinol Diphosphate; Traitement du Cancer par un Remede Radioactif: Le Diphosphate Tetrasodique de Methyl-2 Naphtoquinone-1,4 Tritie; 041b 0435 0447 0435 043d 0414 ; Tratamiento del Cancer con la Sal Tetrasodica del Acido 2-Metil-1,4-Naftoquinon Difosforico Marcada con Tritio." IAEA.
@misc{etde_22188135,
title = {The Treatment of Cancer by a Radioactive Drug: Tritium-Labelled Tetra-Sodium 2-Methyl-1:4-Naphthaquinol Diphosphate; Traitement du Cancer par un Remede Radioactif: Le Diphosphate Tetrasodique de Methyl-2 Naphtoquinone-1,4 Tritie; 041b 0435 0447 0435 043d 0414 ; Tratamiento del Cancer con la Sal Tetrasodica del Acido 2-Metil-1,4-Naftoquinon Difosforico Marcada con Tritio}
author = {Marrian, D. H., Marshall, Barbara, Mitchell, J. S., and Simon-Reuss, I.}
abstractNote = {The action of tetra-sodium 2-methyl-1: 4-naphthaquinoI diphosphate (''Synkavit''-Roche Products) as a radiosensitizer will be reviewed together with earlier methods of labelling this and similar molecules. The synthesis of this compound labelled with tritium has been accomplished so as to yield a radiochemically pure drug of specific activity 28 c/mmole (1 atom of tritium/molecule). It will be shown that this compound enters the living cell very rapidly both in-vivo and in-vitro and that cultures of malignant cells incorporate the label to a much greater extent than cultures of normal cells under identical conditions. Preliminary investigations on the use of this drug on patients with advanced, and often otherwise, refractory, malignant conditions will be described; uptake by the bone marrow is less than by the tumour, sometimes by a factor of 5. (author) [French] Les auteurs examinent l'action du diphosphate tetrasodique de methyl-2- naphtoquinone-1,4 ('Synkavit'-Produits Roche) comme radiosensibilisateur, ainsi que les methodes plus anciennes de marquage de ces molecules et de molecules analogues. On a fait la synthese de ce compose marque au tritium, de facon a obtenir un produit pharmaceutique radiochimiquement pur, dont l'activite specifique est de 28 curies par millimole (1 atome de tritium par molecule). Les auteurs demontrent que ce compose penetre tres rapidement dans la cellule vivante, tant in vivo qu'in vitro, et que les cultures de cellules malignes fixent l'indicateur dans une mesure beaucoup plus large que ne le feront les cellules normales dans les memes conditions. Les auteurs exposent les resultats de recherches preliminaires sur l'emploi de ce remede pour soigner des malades atteints de tumeurs malignes avancees et souvent refractaires a tout autre traitement. L'absorption par la moelle osseuse est inferieure, parfois de 5 fois, a l'absorption par la tumeur. (author) [Spanish] Los autores describen la accion radiosensibilizadora de la sal tetrasodica del acido 2-metil-l,4-naftoquinon-difosforico (''Synkavit'' Roche), asi como algunos de los metodos que se han empleado para marcar este y otros compuestos analogos. Sintetizaron el compuesto tritiado en forma de obtener una substancia radioquimicamente pura de 28 c/mmol (1 atomo de tritio por molecula) de actividad especifica. Demuestran que este producto penetra muy rapidamente en las celulas vivas, tanto in vivo como in vitro y que, en igualdad de condiciones los cultivos de celulas malignas incorporan en grado mucho mayor el compuesto marcado que los cultivos de celulas normales. Describen las investigaciones preliminares del empleo clinico de ese producto en casos avanzados de tumores malignos que suelen ser refractarios a otros tratamientos, observandose que la medula osea absorbe menor cantidad del compuesto que el tumor (en algunas ocasiones, hasta cinco veces menos). (author) [Russian] Dejstvie tetrasoda - 2-metil-1: 4- naftagidrohinondifosfata (Sinkavit - proizvodstvo Roshe) v kachestve radio- senitajzera obsuzhdaetsja narjadu s bolee rannimi metodami mechenija jetih i podob- nyh molekul. Sintez jetogo soedinenija, mechennogo tritiem, byl sdelan dlja togo, chtoby polu- chit' radiohimicheskoe chistoe lekarstvo s udel'noj aktivnost'ju v 28 kjuri/mil- limol' (odin atom tritija na molekulu). Budet pokazano, chto jeto soedinenie bystro vhodit v zhivuju kletku kak v este- stvennyh, tak i i laboratornyh uslovijah i chto kul'tury zlokachestvennyh kletok pogloshhajut mechenye atomy v gorazdo bol'shem ob{sup e}me, chem kul'tury normal'nyh kletok pri teh zhe uslovijah. Budut opisany predvaritel'nye issledovanija primenenija jetogo lekarstva na pacientah, imejushhih zlokachestvennye opuholi i nahodjashhihsja v tjazhelom ili neizlechimom sostojanii; usvoenie kostnym na kojefficient 5 mozgom nizhe, chem usvoenie opuhol'ju. (author)}
place = {IAEA}
year = {1962}
month = {Feb}
}